Alnylam Pharmaceuticals

Alnylam Pharmaceuticals

Yahoo Finance • 2 days ago

Alnylam Pharmaceuticals authorizes $1B share repurchase program

* Alnylam Pharmaceuticals (ALNY [https://seekingalpha.com/symbol/ALNY]) announced [https://seekingalpha.com/pr/20714113-alnylam-announces-1-billion-share-repurchase-program-and-change-in-commercial-leadership] that its board has authoriz... Full story

Yahoo Finance • 2 days ago

Tax-loss selling candidates: the worst-performing US large caps of 2026

Investing.com -- A screen of US large caps (over $5B) with year-to-date losses beyond 35% returned 49 matches. These are the 12 worst. Values are index snapshots and may lag live prices. Still guessing which stocks will beat the market? O... Full story

Yahoo Finance • 2 days ago

Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., November 04, 2026--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare C... Full story

Yahoo Finance • 2 days ago

What Could Alnylam Pharmaceuticals (ALNY) Five Year HELIOS B Data Change?

Alnylam Pharmaceuticals (NasdaqGS:ALNY) plans to present five-year HELIOS-B data on AMVUTTRA at major medical meetings in 2026. The company will share long-term efficacy and safety findings from the pivotal HELIOS-B trial at the American H... Full story

Yahoo Finance • 6 days ago

5 Best High Growth Stocks Outside Big Tech

The market's growth leadership has become abnormally concentrated in a small number of mega-cap technology stocks, leaving investors with fewer obvious opportunities to find rapid earnings growth outside of the AI trade. Ten AI-related sto... Full story

Yahoo Finance • 7 days ago

BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says

BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT N... Full story

Yahoo Finance • 7 days ago

Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and Roche

Company Logo Profiles Roche Diagnostics, Thermo Fisher Scientific, Merck KGaA, Agilent Technologies and Silence Therapeutics, covering their RNAi technology market activities. Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Ribonucleic Acid (... Full story

Yahoo Finance • 7 days ago

Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA Delivery

Company Logo Boost ROI via targeted siRNA delivery, personalized therapies, pipeline-expanding acquisitions, and focus on renal, rare, neurological and oncology indications. Dublin, Oct. 30, 2026 (GLOBE NEWSWIRE) -- "Gene Silencing Thera... Full story

Yahoo Finance • 7 days ago

US Stock Market Today: S&P 500 Futures Drop On Energy Inflation And Wage Risks

The Morning Bull - US Market Morning Update Friday, Oct, 30 2026 US stocks head into Friday under pressure, with S&P 500 and Nasdaq futures pointing lower as investors refocus on global inflation rather than growth worries. The dominant d... Full story

Yahoo Finance • 7 days ago

What Investors Got Wrong About Alnylam Pharmaceuticals Before A 61% Slide

Alnylam Pharmaceuticals has spent the past year in the headlines, from positive HELIOS-B data to a new AI drug discovery deal with Inceptive Nucleics worth up to US$2b. Investors who held Alnylam Pharmaceuticals over the past year are down... Full story

Yahoo Finance • 9 days ago

Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued Following Brezosiran Data

How the brezosiran data frames Alnylam Pharmaceuticals today Alnylam Pharmaceuticals (ALNY) just put fresh Phase 1b data for its Huntington's disease candidate brezosiran in front of investors, with early signs of target engagement and an... Full story

Yahoo Finance • 14 days ago

US Stock Market Today: S&P 500 Futures Steady On Strong Jobs And PMI Focus

The Morning Bull - US Market Morning Update Friday, Oct, 23 2026 US stocks look set for a cautiously positive open, with S&P 500 futures hovering slightly higher. The single driver this morning is labor strength, as fresh jobless claims s... Full story

Yahoo Finance • 17 days ago

Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biotechnology company built on RNA interference, a technique that switches off the genes behind certain diseases. At about $31 billion, the stock features on our list of 9 New Contenders for... Full story

Yahoo Finance • 18 days ago

Merck KgaA Is Paying More Than Double for This Gene-Silencing Biotech, Which Is Soaring 125%

Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion. Continue Reading... Full story

Yahoo Finance • 18 days ago

Why Merck KGaA Is Paying a 130% Premium For This Gene-Silencing Tech

Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion. Continue Reading... Full story

Yahoo Finance • 21 days ago

RNAi drug developer City climbs after upsized IPO

[Magnifying Glass Highlighting IPO Concept on Minimal Yellow Background] City Therapeutics (CTY [https://seekingalpha.com/symbol/CTY]), a developer of a novel treatment class known as RNA interference therapies, added more than 20% on Fri... Full story

Yahoo Finance • last month

US Stock Market Today: S&P 500 Futures Steady As Traders Weigh Global Factory Strength

The Morning Bull - US Market Morning Update Friday, Oct, 2 2026 US stock futures are mixed in early trade, with E-mini S&P 500 contracts roughly flat while Nasdaq-100 futures edge higher. Investors are weighing strong factory readings fro... Full story

Yahoo Finance • last month

AMVUTTRA® (vutrisiran) ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Shine a Light on the Often-Missed Signs of ATTR-CM

Dr. Rajeev Mohan sitting in his office, in conversation with Pete and Kari Shaw. – Launching on World Heart Day, Retired Professional Football Player Pete Shaw Shares How Symptoms Attributed to Football and Aging Led to a Delayed ATTR-CM... Full story

Yahoo Finance • 2 months ago

4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day

Alzheimer's Disease International ("ADI") observes Sept. 21 as World Alzheimer's Day, while September is marked as World Alzheimer's Month to raise awareness about Alzheimer's disease (AD) and other forms of dementia. The 2026 campaign — T... Full story

Yahoo Finance • 2 months ago

Slate Medicines Names Kenneth Koblan as Chief Scientific Officer

By Karen Roman Slate Medicines Inc. said it appointed Kenneth Koblan, PhD, as its new Chief Scientific Officer, having previously served as Head of Research and Development at Vesalius Therapeutics, and at Sumitomo Pharma America as Chief... Full story